TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
Key facts
- Who runs it
- Inflammatix
- Where
- Baltimore and Peoria, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- People taking part
- 320 people enrolled
- Started
- 8 Nov 2024
- Ended
- 10 Mar 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- TriVerity Test
- Record updated
- 28 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Age ≥18 years
- Participant presents to ED with ALL of the below:; 2.1. Suspected acute infection (e.g., respiratory, urinary, abdominal, skin \& soft-tissue infection, meningitis/encephalitis, or any other infection), and 2.2. Either heart rate >100 beats per minute or/and temperature >38C. 2.3. NOT immediately roomed in a primary designated treatment location,( i.e., they can be in the waiting room, ED triage hallways, and/or ED staging area/fast track area)
- Able to provide informed consent, or consent by legally authorized representative
- Reachable via confirmed working cell phone (with backup contact number) and willing to respond to follow-up safety checks (see below for details)
Who cannot take part
- Patient-reported treatment with systemic antibiotics, systemic antiviral agents or systemic antifungal agents within the past 7 days prior to presentation in the waiting room of the ED. Participants will not be excluded for use of:; Antiviral treatment for chronic viral infections, i.e., HIV, hepatitis B and hepatitis C; Topical antibiotics, topical antivirals or topical antifungal agents; Anti-herpes prophylaxis aiding suppression of a recuring herpes infection; Single dose of one or combination of peri-operative (prophylactic) antibiotics
- Patients receiving palliative or hospice care, or those receiving limited interventional care (see Appendix B)
- Participants receiving experimental therapy or already enrolled in an interventional clinical trial in which a subject receives some type of intervention, which can include but is not limited to investigational drugs, medical devices, or vaccines. Participants that are enrolled in non-interventional or observational clinical trials will be allowed to participate in this clinical trial
- Participants previously enrolled in the present clinical trial
- Prisoners, mentally disabled, or unable to give consent. Should the patient not be able to provide informed consent the legally authorized representative can provide the consent on behalf of the patient
Where in United States
- Johns Hopkins Department of Emergency MedicineBaltimore, United States
- OSF HealthCare Saint Francis Medical CenterPeoria, United States
About the trial
What the trial wants to find out
A pre/post interventional use trial, with ED patients who are initially triaged to locations other than a dedicated patient room in the main ED (e.g., waiting room, hallway bed, and/or the staging area/fast track area) with suspected infection and tachycardia or fever will be enrolled. Study conduct will be performed under an Investigational Device Exemption (IDE) from the Food and Drug Administration (FDA). Participants in the pre-phase, treated with standard of care, will be gathered from a retrospective database using propensity matching, whereas participants in the post-phase will be managed incorporating the TriVerity™ Acute Infection and Sepsis Test results with standardized guidance for interpretation and resulting management actions. Many outcomes will be captured and compared between the pre- and post-phase phases including sepsis bundle compliance, patient disposition, appropriate use of antimicrobials (antibiotics and antivirals) and health economic findings. Safety measures for participants in the post-phase will include patient follow-up at predefined time points. The objective is to demonstrate improvement of patient management when incorporating the TriVerity Test result compared to standard of care. Improvements based on diagnostic (bacterial vs viral vs non-infectious inflammation) and prognostic (need for 7-day ICU level care) readouts of the TriVerity Test result will be tracked.
The 2 groups in the trial
- Pre-phase standard of careNo study treatment, for comparison
Participants in the pre-phase, treated with standard of care, will be gathered from a retrospective database using propensity matching.
- Post-phase TriVerity TestTreatment being tested
Participants in the post-phase will be managed incorporating the TriVerity Test results with standardized guidance for interpretation and resulting management actions.
Treatment: TriVerity Test
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 28 September 2026